Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) announced a significant shareholder return plan, intending to utilize up to HKD 1.2 billion over the next three years through dividends and share buybacks [2][3]. Group 1: Shareholder Return Plan - The company plans to distribute annual dividends amounting to no less than 50% of the net profit attributable to shareholders for the next three complete financial years [3]. - The company has received authorization to repurchase up to 23.5796 million shares under the existing buyback authorization, with 605,500 shares already repurchased as of November 4 [3][5]. Group 2: Market Reaction and Analysis - Following the announcement, the stock price of Meili Tianyuan rose by 3.13%, reaching HKD 30.34 per share [2]. - Analysts believe the feasibility of the shareholder return plan hinges on the company's ability to deliver stable performance, which is essential for sustaining shareholder returns [2][5]. - The management's decision to implement this plan is seen as a confidence signal in the company's long-term value, especially amid recent stock price declines [5]. Group 3: Future Considerations - The success of the shareholder return plan will ultimately depend on the company's ability to fulfill its commitments and demonstrate performance through quarterly results [5]. - Meili Tianyuan is also anticipated to be a contender for the "Top 100 Hong Kong Stocks" list, which could further enhance its market position [5].
拟12亿港元回馈股东！美丽田园股价涨逾3%